GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (LSE:0JYO) » Definitions » Operating Margin %

BB Biotech AG (LSE:0JYO) Operating Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is BB Biotech AG Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. BB Biotech AG's Operating Income for the three months ended in Dec. 2023 was €0.00 Mil. BB Biotech AG's Revenue for the three months ended in Dec. 2023 was €117.88 Mil. Therefore, BB Biotech AG's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for BB Biotech AG's Operating Margin % or its related term are showing as below:


LSE:0JYO's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -166.59
* Ranked among companies with meaningful Operating Margin % only.

BB Biotech AG's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

BB Biotech AG's Operating Income for the three months ended in Dec. 2023 was €0.00 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.


BB Biotech AG Operating Margin % Historical Data

The historical data trend for BB Biotech AG's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Operating Margin % Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BB Biotech AG Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BB Biotech AG's Operating Margin %

For the Biotechnology subindustry, BB Biotech AG's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BB Biotech AG's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Operating Margin % distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Operating Margin % falls into.



BB Biotech AG Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

BB Biotech AG's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0 / -211.613
=0.00 %

BB Biotech AG's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0 / 117.88
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BB Biotech AG  (LSE:0JYO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


BB Biotech AG Operating Margin % Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG (LSE:0JYO) Business Description

Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (LSE:0JYO) Headlines

No Headlines